Caligan Partners LP Purchases 124,5 Shares of I-Mab

IMAB Stock  USD 0.90  0.02  2.17%   
About 77 percent of I Mab's investors are selling. The analysis of the overall investor sentiment regarding I Mab suggests that quite a large number of traders are terrified. The current market sentiment, together with I Mab's historical and current headlines, can help investors time the market. In addition, many technical investors use I Mab stock news signals to limit their universe of possible portfolio assets.
  
Caligan Partners LP grew its position in I-Mab by 3.7 percent in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 3,499,330 shares of the companys stock after purchasing an additional 124,5 shares during the period. I-Mab accounts for 1.4 percent of Caligan Partners LPs holdings, making the stock its 10th largest position.

Read at thelincolnianonline.com
news
  

I Mab Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards I Mab can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

I Mab Fundamental Analysis

We analyze I Mab's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of I Mab using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of I Mab based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Working Capital

Working Capital Comparative Analysis

I Mab is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

I Mab Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with I Mab stock to make a market-neutral strategy. Peer analysis of I Mab could also be used in its relative valuation, which is a method of valuing I Mab by comparing valuation metrics with similar companies.

Peers

I Mab Related Equities

DSGNDesign Therapeutics   11.50   
0%
100.0%
LYELLyell Immunopharma   6.61   
0%
57.0%
GLUEMonte Rosa   5.41   
0%
47.0%
APLSApellis Pharmaceuticals   4.11   
0%
35.0%
ERASErasca   3.13   
0%
27.0%
KRYSKrystal Biotech   1.97   
0%
17.0%
KYMRKymera Therapeutics   1.69   
0%
14.0%
CGEMCullinan Oncology   1.63   
0%
14.0%
FHTXFoghorn Therapeutics   1.62   
0%
14.0%
STTKShattuck Labs   0.82   
0%
7.0%
NRIXNurix Therapeutics   0.49   
0%
4.0%
BPMCBlueprint Medicines   0.41   
3.0%
0%
ASNDAscendis Pharma   0.74   
6.0%
0%
RVMDRevolution Medicines   0.99   
8.0%
0%
AKROAkero Therapeutics   2.22   
19.0%
0%
IMVTImmunovant   10.24   
89.0%
0%

Complementary Tools for IMAB Stock analysis

When running I Mab's price analysis, check to measure I Mab's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy I Mab is operating at the current time. Most of I Mab's value examination focuses on studying past and present price action to predict the probability of I Mab's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move I Mab's price. Additionally, you may evaluate how the addition of I Mab to your portfolios can decrease your overall portfolio volatility.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Stocks Directory
Find actively traded stocks across global markets
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Fundamental Analysis
View fundamental data based on most recent published financial statements
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios